4.3 Article

Antiretroviral Therapy in HIV-Infected Elite Controllers: Impact on Gut Immunology, Microbial Translocation, and Biomarkers of Serious Non-AIDS Conditions

Journal

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAI.0000000000000359

Keywords

HIV; elite controllers; antiretroviral therapy; gut immunology; microbial translocation; serious non-AIDS conditions; inflammation

Funding

  1. Ontario HIV Treatment Network [ROGB-G123]
  2. Canadian Institutes of Health Research/Canadian Digestive Health Foundation (CIHR/CDHF)
  3. CIHR (Emerging HIV Team Grant) [HET85518]
  4. Canadian Research Chair Program
  5. Intramural Research Program of the National Institutes of Allergy and Infectious Diseases, National Institute of Health

Ask authors/readers for more resources

Elite controllers (ECs) maintain undetectable HIV viral loads without antiretroviral therapy (ART) but are at increased risk of serious non-AIDS conditions (SNA). We assessed the impact of ART in ECs on gut immune dysfunction and biomarkers predicting SNA (blood CD4/CD8 ratio, plasma IL-6, D-dimer levels). At baseline, ECs had elevated IL-6 and D-dimer levels and reduced CD4/CD8 ratio compared with HIV-uninfected controls, but no difference in microbial translocation or gut CD4 subsets. ART increased CD4/CD8 ratio but did not normalize IL-6 and D-dimer levels. EC SNA pathogenesis may be independent of gut immune dysfunction, and resolution may require prolonged ART.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available